Systematic detection of mosaicism by using digital NGS reveals three new MEN1 mosaicisms.
MEN1
NGS
de novo
deep-sequencing
digital NGS
hyperparathyroidism
mosaic
mosaicism
pancreatic neuroendocrine tumor
pituitary adenoma
thymic tumor
unique molecular identifier
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
received:
02
09
2022
accepted:
16
09
2022
pubmed:
17
9
2022
medline:
17
9
2022
entrez:
16
9
2022
Statut:
epublish
Résumé
Mosaicism is a feature of several inherited tumor syndromes. Only a few cases of mosaicism have been described in multiple endocrine neoplasia type 1 (MEN1). Next-generation sequencing (NGS) offers new possibilities for detecting mosaicism. Here, we report the first study to systematically look for MEN1 mosaicism, using blood DNA, in MEN1-suspected patients but without MEN1 pathogenic variants (PV) in a heterozygous state. Digital targeted NGS, including unique molecular identifiers (UMIs), was performed in routine practice, and the analytic performance of this method was verified. Among a cohort of 119 patients harboring from 2 to 5 MEN1 lesions, we identified 3 patients with MEN1 mosaic PVs. The allele frequencies ranged from 2.3 to 9.5%. The detection rate of MEN1 mosaicism in patients bearing at least 3 MEN1 lesions was 17% (3/18). No cases were detected in patients with two lesions. We report here three new cases with MEN1 mosaicism. This study examined the performance of UMI in the diagnosis of MEN1 mosaicism in routine practice, and our results underline that the frequency of mosaicism is probably underestimated in patients with suspected MEN1.
Identifiants
pubmed: 36112497
doi: 10.1530/EC-22-0093
pii: e220093
pmc: PMC9578105
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Nat Methods. 2011 Nov 20;9(1):72-4
pubmed: 22101854
PLoS One. 2013;8(3):e60525
pubmed: 23536913
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
Hum Mutat. 2008 Jan;29(1):22-32
pubmed: 17879353
Neuro Oncol. 2018 Jun 18;20(7):917-929
pubmed: 29409008
J Mol Diagn. 2019 May;21(3):462-470
pubmed: 30731206
DNA Res. 2012 Apr;19(2):143-52
pubmed: 22279087
Eur J Endocrinol. 2019 Feb 1;180(2):K15-K19
pubmed: 30481156
BMC Med. 2016 Nov 15;14(1):182
pubmed: 27842554
Genet Med. 2005 Feb;7(2):131-8
pubmed: 15714081
BMC Genomics. 2017 Jan 3;18(1):5
pubmed: 28049435
J Med Genet. 1992 Dec;29(12):841-6
pubmed: 1479598
Eur J Endocrinol. 2022 May 24;187(1):K1-K6
pubmed: 35521764
Science. 1997 Apr 18;276(5311):404-7
pubmed: 9103196
J Clin Endocrinol Metab. 2007 Sep;92(9):3389-95
pubmed: 17623761
World J Surg. 2000 Nov;24(11):1437-41
pubmed: 11038219
Oncol Res Treat. 2018;41(10):634-642
pubmed: 30145586
Haematologica. 2020 Jul 16;105(10):e535
pubmed: 33054100
Fam Cancer. 2020 Oct;19(4):307-310
pubmed: 32468491
Eur J Endocrinol. 2019 Feb 1;180(2):L1-L3
pubmed: 30444722
Eur J Hum Genet. 2014 Sep;22(9):1149-52
pubmed: 24301059
Biotechniques. 2017 Nov 1;63(5):221-226
pubmed: 29185922
World J Surg. 2010 Feb;34(2):249-55
pubmed: 19949948
Cancer Genet. 2017 Oct;216-217:79-85
pubmed: 29025599
Ann Endocrinol (Paris). 2006 Dec;67(6):581-7
pubmed: 17194968
J Med Genet. 1992 Dec;29(12):847-52
pubmed: 1479599
Genet Med. 2020 Jan;22(1):53-59
pubmed: 31273341